Sucrosomial Iron Phospholipid Complex for Gut Microbiota Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current iron-based supplements often exacerbate gastrointestinal infections and disorders by increasing pathogenic bacteria in the gut microbiota, particularly Proteobacteria, leading to dysbiosis and reduced iron absorption, and fail to effectively treat iron deficiency without causing adverse effects.
Innovation Solution
An iron formulation in solid form comprising an iron (III) salt, a phospholipid, and a sucrester, known as Sucrosomial® Iron, which reduces pathogenic bacteria and increases beneficial bacteria, thereby maintaining gut microbiota balance and preventing gastrointestinal infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional iron-based supplements (Fe II) are administered to treat iron deficiency, then iron levels are improved, but pathogenic bacteria (Proteobacteria) increase causing gastrointestinal inflammation
Solution Approach 1:
The patent uses a phospholipid complex as an intermediary carrier to deliver iron (III) to the intestinal mucosa. This phospholipid-mediated delivery system prevents direct contact between free iron and pathogenic bacteria, thereby eliminating the proliferative effect while maintaining iron supplementation benefits
Solution Approach 2:
The patent changes the oxidation state of iron from Fe (II) to Fe (III) and modifies its chemical form by creating a phospholipid complex. This parameter change transforms iron from a substance that promotes pathogenic bacterial growth into one that does not, while maintaining therapeutic efficacy
2Quantity of substance
If iron supplementation is increased to treat iron deficiency, then iron absorption is improved, but gastrointestinal side effects worsen
Solution Approach 1:
The phospholipid complex acts as a protective intermediary that enables higher doses of iron to be administered without causing gastrointestinal irritation. The complex shields the intestinal mucosa from direct exposure to free iron, reducing side effects while maintaining absorption efficiency
Solution Approach 2:
The invention creates a composite material consisting of iron (III) bound to phospholipids. This composite structure combines the therapeutic properties of iron with the protective and emulsifying properties of phospholipids, reducing gastrointestinal toxicity while enhancing absorption
3Stability of the object's composition
If iron (III) formulations are used to reduce pathogenic bacteria, then gut microbiota balance is improved, but iron absorption efficiency may be reduced
Solution Approach 1:
The phospholipid complex serves as a mediator that facilitates iron (III) absorption without requiring reduction to Fe (II). The phospholipid carrier enables direct uptake of Fe (III) by intestinal cells, maintaining absorption efficiency while preserving the beneficial effect on gut microbiota
Solution Approach 2:
The patent changes the delivery mechanism parameter by using phospholipid-mediated transport instead of traditional reduction-based absorption. This allows Fe (III) to be absorbed efficiently in its oxidized state, maintaining both microbiota balance and iron absorption efficacy
Data Source
AI summary
The present invention relates to an iron-based formulation and compositions thereof for use in a method for the treatment of a gastrointestinal inflammation, in a therapeutic or non-therapeutic treatment of an iron deficiency by administering said formulation to a subject, wherein said iron formulation is capable of reducing (or maintaining constant) the amount of pathogenic bacteria present in the gut microbiota of the treated subject and, preferably, also capable of increasing the variety of the gut microbiota of the treated subject.